Dr. Susan Learned, Scientific Advisory Board, ReForma Therapeutics

Dr. Susan Learned

Scientific Advisor

“ReForma’s business model marries expertise in innovative formulation development, regulatory affairs and clinical drug development with the aim of substantially improving patient outcomes, efficacy, safety and cost-effectiveness of medicines.  Their mission and vision are aligned with my own, and thus I’m very happy to help this talented team ensure that these are successfully realized.”

Dr. Susan Learned, M.D., Pharm.D., Ph.D., is the President and Founder of Learned Consulting Group, LLC, which largely provides overall R&D, clinical pharmacology and medicines development strategic and execution support to pharmaceutical companies. She currently is Chief Scientific Officer and Head of R&D for 2 biotechs and is Chief Development and Medical Officer for a third. She supports other clients as a Scientific Advisory Board member, Data Safety Monitoring Board member or as a Scientific Advisor to the Board of Directors or managing equity organization(s).

From 2015 - 2021, she served as Senior Vice President of Global Medicines Development at Indivior, a global pharmaceutical company based in Richmond, VA focused on developing medicines for patients with addictions and comorbid disorders. In that role, she was accountable for all drug discovery through post Phase IV drug development activities, including post-approval REMS programs and led all associated clinical and nonclinical disciplines. Susan’s 29+ years of expertise in the pharmaceutical industry spans all phases of drug discovery and development. She has managed large, global multidisciplinary drug discovery and development organizations, led the design of innovative clinical trials to make efficient business decisions, implemented biomarkers and translational medicine tools across therapeutic areas, led business development strategies and operations, developed high performing teams, and provided mentorship for globally diverse team members in leadership roles.

Prior to joining Indivior, Dr. Learned was the VP, Medicines Development Lead and Franchise Lead for Psoriasis and Atopic Dermatitis at Stiefel, GSK’s Dermatology company. In that role, she led medicines development, including strategic and operational teams accountable for all areas of R&D and Commercial strategy for all assets from preclinical development through life cycle management, as well as all support functions. Susan was previously VP of Discovery Medicine for GSK in China where she set up the early development neuroscience organization for GSK in Shanghai by leading all clinical development activities for the global neurology pipeline. Previous roles included being the Head of Neurosciences Discovery Scientific Licensing for GSK’s Worldwide Business Development organization, Head of GSK’s Neurosciences Discovery Medicine, and Head of Clinical Pharmacology and Discovery Medicine for GSK’s Psychiatry Center for Excellence in Drug Discovery. Susan’s key contributions have included over 60 worldwide regulatory approvals, including 12 medicines in the psychiatry, addiction medicine, neurology, oncology and dermatology therapeutic areas.

Susan obtained her BS Pharmacy and MD degrees at Union University’s Albany College of Pharmacy and Albany Medical College, Albany, NY, her internal medicine residency training at Erie County Medical Center, Buffalo, NY, and her PharmD and PhD (neurobehavioral clinical pharmacology) degrees at the Medical College of Virginia / Virginia Commonwealth University.

She has served on numerous boards, including the National Institute on Drug Abuse’s Medications Development Advisory Board, Albany College of Pharmacy and Health Sciences’ Board of Trustees, The Medical College of Virginia Foundation Board of Trustees, the Medical College of Virginia / VCU’s School of Pharmacy Graduate Advisory Board and the School of Pharmacy and School of Medicine’s National Advisory Council.

She has also been a Visiting Professor in the FDA’s Neurosciences division on the use of neuroimaging in drug development and her work with the SFDA / CFDA in China has helped to influence change in that Agency and encourage adoption of Western regulatory guidances.